52
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial

, , , , , & show all
Pages 499-508 | Published online: 05 Feb 2018

References

  • KochanekKDMurphySLJiaquanXAriasEMortality in the United States, 2013. National Center for Health Statistics (NCHS) Data Brief. No 1782014 Available from: http://www.cdc.gov/nchs/data/databriefs/db178.pdfAccessed May 9, 2017
  • National Heart, Lung and Blood InstituteMorbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood DiseasesBethesda, MDNational Institutes of Health2012 Available from: https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdfAccessed May 9, 2017
  • FosterTSMillerJDMartonJPCaloyerasJPRussellMWMenzinJAssessment of the economic burden of COPD in the U.S.: a review and synthesis of the literatureCOPD20063421121817361502
  • American Lung AssociationTrends in COPD: Chronic Bronchitis and Emphysema: Morbidity and Mortality2013 Available at http://www.lung.org/finding-cures/our-research/trend-reports/copd-trend-report.pdfAccessed May 9, 2017
  • PatelJGNagarSPDalalAAIndirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United StatesInt J Chron Obstruct Pulmon Dis2014928930024672234
  • JonesPMiravitllesMvan der MolenTKulichKBeyond FEV(1) in COPD: a review of patient-reported outcomes and their measurementInt J Chron Obstruct Pulmon Dis2012769770923093901
  • RennardSIFarmerSGExacerbations and progression of disease in asthma and chronic obstructive pulmonary diseaseProc Am Thorac Soc200412889216113418
  • MiravitllesMMolinaJNaberanKFactors determining the quality of life of patients with COPD in primary careTher Adv Respir Dis200712859219124350
  • ShavroSAEzhilarasuPAugustineJBechtelJJChristopherDJCorrelation of health-related quality of life with other disease severity indices in Indian chronic obstructive pulmonary disease patientsInt J Chron Obstruct Pulmon Dis2012729129622615528
  • ReardonJZLareauSCZuWallackRFunctional status and quality of life in chronic obstructive pulmonary diseaseAm J Med200611910 suppl 1323716996897
  • Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPD2015 Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/Accessed May 9, 2017
  • BentsenSBHenriksenAHWentzel-LarsenTHanestadBRWahlAKWhat determines subjective health status in patients with chronic obstructive pulmonary disease: importance of symptoms in subjective health status of COPD patientsHealth Qual Life Outcomes2008611519094216
  • van der MolenTMiravitllesMKocksJWCOPD management: role of symptom assessment in routine clinical practiceInt J Chron Obstruct Pulmon Dis2013846147124143085
  • DonohueJFHananiaNAMakeBOne-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPDChest201414661531154225451347
  • BaumgartnerRAHananiaNACalhounWJSahnSASciarappaKHanrahanJPNebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trialClin Ther200729226127817472819
  • AgustiACalverleyPMCelliBCharacterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
  • AgustiAGCOPD, a multicomponent disease: implications for managementRespir Med200599667068215878483
  • WedzichaJAThe heterogeneity of chronic obstructive pulmonary diseaseThorax200055863163210899236
  • StullDEHoughtonKIdentifying differential responders and their characteristics in clinical trials: innovative methods for analyzing longitudinal dataValue Health201316116417623337228
  • StullDEHoughtonKPetrilloJInnovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trialsISPQR Connect20131958
  • WillkeRJZhengZSubediPAlthinRMullinsCDFrom concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primerBMC Med Res Methodol20121218523234603
  • StullDEWiklundIGaleRCapkun-NiggliGHoughtonKJonesPApplication of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPDContemp Clin Trials20113281882821762787
  • JonesPWQuirkFHBaveystockCMThe St George’s Respiratory QuestionnaireRespir Med199185suppl B2531 discussion 33–371759018
  • JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory QuestionnaireAm Rev Respir Dis1992145132113271595997
  • TofighiDEndersCKIdentifying the correct number of classes in growth mixture modelsHancockGSamuelsonKAdvances in Latent Variable Mixture ModelsCharlotte, NCInformation Age Publishing2008317341
  • KewKMMavergamesCWaltersJALong-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201310CD010177